Published in Cancer Discovery, early trials show that sevabertinib can shrink tumours in patients with HER2 exon 20, a mutated lung cancer found in roughly 2-3 per cent of cases.
Harshil Dave, a researcher at IIT Gandhinagar, co-authored the paper with his colleagues Hitasha Vithalani, Hemant Singh, Indu Yadav, and Abhinav Jain, among others.
The Global Cancer Observatory predicts that cancer cases will rise to 32.6 million worldwide by 2045, with India already carrying the third-highest cancer burden globally.
Experts say ‘surge in cancer cases remains relatively modest on a per capita basis, but actual burden may be higher due to persistent underreporting in rural, underserved regions’.
Cancer imposes catastrophic health expenditure in India, with medicines constituting over 60% of out-of-pocket expenditure. Research shows wide price variations, limited cost containment.
Study published in Nature Cell Biology is fundamental in understanding the ways in which cancer cells can develop drug resistance, one of the main causes of relapse.
Osaka University professor Shimon Sakaguchi, Princeton PhD student Mary E. Brunkow, and US-based Parker Institute for Cancer Immunotherapy director Fred Ramsdell win the Nobel Prize in medicine.
Analysis by network of thousands of researchers and academics from around the world relied on cancer incidence & mortality rates for 204 countries and territories for 47 cancer types.
While the Russia-Ukraine war saw the BJP projecting PM Modi as a ‘vishwaguru’ who could end international conflicts, the party has made a nuanced shift in its electoral strategy vis-à-vis the West Asia war.
Report on impact of AI emergence—drawing upon depositions from several ministries—confirms that the developments come in the absence of AI laws or considerations over them.
It’s easy to understand why the government can’t speak the hard truth. When this war ends, as all wars do, India’s interests will lie with both the winner and the loser.
COMMENTS